ArticleHeliyon2024
Radiomics analysis of intratumoral and different peritumoral regions from multiparametric MRI for evaluating HER2 status of breast cancer: A comparative study.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- MRI-based habitat and peritumoral radiomics for predicting HER2 status in breast cancer: a multicenter study.Scientific reports · 2026Article
- Value of intratumoral and peritumoral radiomics based on DCE-MRI in predicting HER2-low and HER2-zero in breast cancer.BMC medical imaging · 2026Article
- Stratified prediction of HER2 status in breast cancer by integrating intratumoral and peritumoral radiomics from DCE-MRI.BMC cancer · 2026Article
- Multiparametric MRI-based radiomics of whole-tumor and habitat regions for predicting HER2 status in young breast cancer: a two-center study.Frontiers in oncology · 2026Article
- A radiomics-deep learning nomogram integrating intratumoral and peritumoral DCE-MRI features for pCR prediction in breast cancer.Frontiers in oncology · 2026Article
- Multimodal PA/US imaging and radiomics for the prediction of HER2-zero, -low, and -positive breast cancers: A novel approach for targeted therapy selection.Photoacoustics · 2025Article
- Radiology-based artificial intelligence for predicting targeted therapy response in pan-cancer: a comprehensive review.Journal of translational medicine · 2025Review
- Multimodal imaging and advanced quantitative techniques for HER-2 status prediction in breast cancer.Discover oncology · 2025Review
- Intratumoral and peritumoral ultrasound radiomics analysis for predicting HER2-low expression in HER2-negative breast cancer patients: a retrospective analysis of dual-central study.Discover oncology · 2025Article
- Comparative analysis of multi-zone peritumoral radiomics in breast cancer for predicting NAC response using ABVS-based deep learning models.Frontiers in oncology · 2025Article
- MRI-Derived Radiomics For Classifying Breast Cancer Molecular Subtypes: a Modeling Approach.Acta informatica medica : AIM : journal of the Society for Medical Informatics of Bosnia & Herzegovina : casopis Drustva za medicinsku informatiku BiH · 2025Article
- Development and validation of a radiomics-based nomogram for predicting two subtypes of HER2-negative breast cancer.Gland surgery · 2024Article
- Predicting axillary lymph node metastasis in breast cancer using a multimodal radiomics and deep learning model.Frontiers in immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the potential of radiomics signatures (RSs) from intratumoral and peritumoral regions on multiparametric magnetic resonance imaging (MRI) to noninvasively evaluate HER2 status in breast cancer. Method: In this retrospective study, 992 patients with pathologically confirmed breast cancers who underwent preoperative MRI were enrolled. The breast cancer lesions were segmented manually, and the intratumor region of interest (ROI Result: The best single-area RSs for predicting HER2 status were DCE_Peri4mm-RS, T2_Peri4mm-RS, and DWI_Peri4mm-RS, yielding areas under the curve (AUCs) of 0.716 (95% confidence interval (CI), 0.648-0.778), 0.706 (95% CI, 0.637-0.768), and 0.719 (95% CI, 0.651-0.780), respectively, in the test set. The optimal RSs combining intratumoral and peritumoral regions for evaluating HER2 status were DCE-T1_Intra + DCE_Peri4mm-RS, T2_Intra + T2_Peri6mm-RS and DWI_Intra + DWI_Peri4mm-RS, with AUCs of 0.752 (95% CI, 0.686-0.810), 0.754 (95% CI, 0.688-0.812) and 0.725 (95% CI, 0.657-0.786), respectively, in the test set. Combining three sequences in the ROI Conclusion: This study systematically explored the influence of the intratumoral region, different peritumoral sizes and their combination in radiomics analysis for predicting HER2 status in breast cancer based on multiparametric MRI and found the optimal RS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.